What is it about?
In this study, we describe the successful validation of a safe pseudotyped virus-based neutralisation assay using serum samples from the first international reference panel for anti-Lassa fever virus antibodies provided by the Medicines and Healthcare products Regulatory Agency (MHRA).
Featured Image
Photo by Mathurin NAPOLY / matnapo on Unsplash
Why is it important?
It is important as it demonstrates that this pseudotype virus-based assay for Lassa virus can be employed for pre-clinical evaluation of candidate vaccines and therapeutics without requiring high-containment facilities.
Perspectives
Very important publication for me as it moves pseudotype virus production and assay development from the research lab into the pre-clinical space. Excellent demonstration of effective collaboration with a key CRO in the vaccine space, VisMederi.
Professor Nigel James Temperton
University of Kent
Read the Original
This page is a summary of: A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison, F1000Research, October 2024, Faculty of 1000, Ltd.,
DOI: 10.12688/f1000research.149578.2.
You can read the full text:
Contributors
The following have contributed to this page
